Search

everythinglearnresearchcommunity

for

Search:↓

A new compound shows promise as a topical treatment for hair loss.

Removing Ctip2 in skin cells causes skin inflammation similar to atopic dermatitis.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Tislelizumab can cause cutaneous lupus erythematosus.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.

Baricitinib is the most effective treatment for alopecia areata.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

The inhibitor affects androgen metabolism but not ovarian function.

Matriptase-2 helps control iron levels by suppressing hepcidin, and its deficiency can cause iron-deficiency anemia.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.

The drug combination was safe and showed promise in treating advanced tumors.

Targeting THY1 can improve skin repair and healing.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.